Related Experiment Video
Updated: Sep 28, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Influence of nitric oxide on the in vitro antiaggregant effect of ticlopidine
J P De La Cruz1, M M Arrebola, A Guerrero
1Department of Pharmacology and Therapetics, School of Medicine, University of Málaga, Campus de Teatinos s/n, Málaga 29071, Spain. jpcruz@uma.es
Abstract:
The aim of this study was to evaluate the influence of leukocyte nitric oxide (NO) production on the antiplatelet aggregant effect of aspirin and ticlopidine. This in vitro study was done with platelets (platelet-rich plasma, PRP) and polymorphonuclear leukocytes (PMNLs) separated from samples of human blood. Collagen-induced platelet aggregation and calcium-dependent NO production by PMNL were quantified. The inhibition of NO production in PRP significantly reduced the antiaggregant affect of aspirin (IC50 2.64-fold greater), whereas it had no significant effect on the effect of ticlopidine (IC50 1.03-fold greater). Incubating PMNL in PRP increased the antiaggregant effect of both aspirin (IC50 5.09-fold lower) and ticlopidine (IC50 10.16-fold lower). The inhibition of NO production in PMNL significantly reduced the antiaggregant effect of both aspirin (IC50 2.21-fold greater) and ticlopidine (IC50 3.26-fold greater). Both drugs increased leukocyte NO production. The concentration of aspirin that raised NO production by 50% was greater than 1000 microM, whereas the concentration of ticlopidine that led to this effect was 9.14 +/- 0.87 microM. We conclude that the effect of ticlopidine on leukocyte NO production may constitute an addition mechanism to the IIb/IIIa glycoprotein complex inactivation in the inhibition of platelet activation.
Related Concept Videos
Nitric Oxide Signaling Pathway
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Therapeutic Drug Monitoring: Affecting Factors
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...

